DE60322509D1 - Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung - Google Patents

Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Info

Publication number
DE60322509D1
DE60322509D1 DE60322509T DE60322509T DE60322509D1 DE 60322509 D1 DE60322509 D1 DE 60322509D1 DE 60322509 T DE60322509 T DE 60322509T DE 60322509 T DE60322509 T DE 60322509T DE 60322509 D1 DE60322509 D1 DE 60322509D1
Authority
DE
Germany
Prior art keywords
igfbp
antisense oligonucleotides
bis
specific antisense
oligonucleotides inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60322509T
Other languages
English (en)
Inventor
Martin Gleave
Maxim Signaevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60322509D1 publication Critical patent/DE60322509D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60322509T 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung Expired - Lifetime DE60322509D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
PCT/CA2003/000061 WO2003062421A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same

Publications (1)

Publication Number Publication Date
DE60322509D1 true DE60322509D1 (de) 2008-09-11

Family

ID=27613360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60322509T Expired - Lifetime DE60322509D1 (de) 2002-01-17 2003-01-17 Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung

Country Status (15)

Country Link
US (11) US20030158143A1 (de)
EP (1) EP1465995B1 (de)
JP (1) JP4491240B2 (de)
KR (2) KR101166214B1 (de)
AT (1) ATE402999T1 (de)
AU (1) AU2003237616B2 (de)
CA (1) CA2469685C (de)
DE (1) DE60322509D1 (de)
DK (1) DK1465995T3 (de)
ES (1) ES2307942T3 (de)
HU (1) HU229452B1 (de)
IL (2) IL162540A0 (de)
NO (1) NO333017B1 (de)
NZ (1) NZ533126A (de)
WO (1) WO2003062421A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163254B1 (de) 1999-02-26 2008-01-30 The University of British Columbia Antisense-therapie für trpm-2
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US20030158143A1 (en) * 2002-01-17 2003-08-21 Martin Gleave Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CA2494766C (en) * 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
AU2003297259A1 (en) * 2002-11-14 2004-06-03 Wyeth Methods and compositions for treating neurological disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
PT1814595E (pt) * 2004-11-23 2014-04-02 Univ British Columbia Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
WO2007030930A1 (en) * 2005-09-13 2007-03-22 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
US8329399B2 (en) * 2006-10-27 2012-12-11 Siu K W Michael Endometrial biomarkers
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
SG10201501496TA (en) 2010-03-01 2015-04-29 Tau Therapeutics Llc Cancer diagnosis and imaging
PE20140647A1 (es) * 2011-05-19 2014-06-05 Teva Pharma Metodo para tratamiento de cancer de pulmon de celulas no pequenas
CN103957923B (zh) 2011-09-12 2018-05-25 卡维昂公司 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂
JP2015512877A (ja) 2012-02-22 2015-04-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌を治療するためのクラステリン阻害剤とｅｇｆｒ阻害剤の併用
CA2844640A1 (en) * 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
JP7441002B2 (ja) * 2015-10-14 2024-02-29 バイオ－パス ホールディングス， インコーポレイテッド リポソーム製剤のためのｐ－エトキシ核酸
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
SG10202008771WA (en) 2016-09-16 2020-10-29 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
EP3585376A4 (de) 2017-02-15 2020-11-25 Cavion, Inc. Calciumkanalinhibitoren
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
CA3061720A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치
MX2021003706A (es) 2018-10-03 2021-11-04 Cavion Inc Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida.

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090705A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
IE913034A1 (en) 1990-08-28 1992-03-11 Chiron Corp New insulin-like growth factor binding protein (igfbp-5)
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AU1313095A (en) 1993-12-23 1995-07-10 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JP4293636B2 (ja) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5910583A (en) 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
EP1163254B1 (de) 1999-02-26 2008-01-30 The University of British Columbia Antisense-therapie für trpm-2
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2000069454A1 (en) 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
EP1191941A4 (de) * 1999-06-21 2006-12-13 Murdoch Childrens Res Inst Methode der prophylaxe und/oder behandlung von erkrankungen
CA2373721C (en) 1999-07-02 2013-10-15 Genentech, Inc. Compounds that bind her2
US7297684B1 (en) * 1999-07-19 2007-11-20 The University Of British Columbia Antisense therapy for hormone-regulated tumors
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
MXPA02006167A (es) 1999-12-21 2004-02-26 Univ Yale Promocion de la angiogenesis con survivina.
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
NZ524274A (en) * 2000-09-14 2004-10-29 Univ British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
EP1390472A4 (de) 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
WO2003035843A2 (en) 2001-10-25 2003-05-01 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
US20030158143A1 (en) * 2002-01-17 2003-08-21 Martin Gleave Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
AU2003237790A1 (en) 2002-05-14 2003-12-02 Baylor College Of Medicine Small molecule inhibitors of her2 expression
CA2494766C (en) 2002-08-21 2015-05-12 The University Of British Columbia Rnai probes targeting cancer-related proteins
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US20040220131A1 (en) 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
CA2539727C (en) * 2003-10-01 2016-11-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
BR112012002102A2 (pt) * 2009-07-30 2017-05-02 Antisense Pharma Gmbh composição farmaceutica e metodo para preparar uma composição farmaceutica

Also Published As

Publication number Publication date
HUP0402543A3 (en) 2012-09-28
US20130096180A1 (en) 2013-04-18
US20110190382A1 (en) 2011-08-04
NZ533126A (en) 2006-04-28
DK1465995T3 (da) 2008-10-20
JP4491240B2 (ja) 2010-06-30
US20100267808A1 (en) 2010-10-21
US8580761B2 (en) 2013-11-12
US7973017B2 (en) 2011-07-05
JP2005514948A (ja) 2005-05-26
US20160002630A1 (en) 2016-01-07
US20060122141A1 (en) 2006-06-08
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
HUP0402543A2 (hu) 2005-03-29
KR101166214B1 (ko) 2012-07-16
WO2003062421A1 (en) 2003-07-31
KR20040085150A (ko) 2004-10-07
US9101646B2 (en) 2015-08-11
EP1465995A1 (de) 2004-10-13
CA2469685C (en) 2013-03-12
US8835401B2 (en) 2014-09-16
KR101265180B1 (ko) 2013-05-29
US8470796B2 (en) 2013-06-25
US8541390B2 (en) 2013-09-24
CA2469685A1 (en) 2003-07-31
US20110196019A1 (en) 2011-08-11
US8252765B2 (en) 2012-08-28
US20130303592A1 (en) 2013-11-14
NO20043401L (no) 2004-10-13
US20120220646A1 (en) 2012-08-30
ES2307942T3 (es) 2008-12-01
EP1465995B1 (de) 2008-07-30
US20120077861A1 (en) 2012-03-29
US20030158143A1 (en) 2003-08-21
US7928082B2 (en) 2011-04-19
ATE402999T1 (de) 2008-08-15
US20080261912A1 (en) 2008-10-23
NO333017B1 (no) 2013-02-18
HU229452B1 (en) 2013-12-30
IL162540A0 (en) 2005-11-20
AU2003237616B2 (en) 2007-07-05
IL162540A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
DE60322509D1 (de) Bispezifische antisense oligonukleotide die igfbp-2 und igfbp-5 inhibieren und deren verwendung
DE60211937D1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
IL197159A (en) Two-stranded rna molecules that complement a sense or antisense strand of a human encoding igfbp-2 and igfbp-5, preparations containing them and their uses
DE60317663D1 (de) Fluorchemische zusammensetzung enthaltend einen fluorierten polyether und dessen verwendung zur behandlung von fasermaterialien
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
ATE374204T1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE433978T1 (de) 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
HK1089501A1 (en) Self-inflating cushion and article of shoe including same
TW200612918A (en) Lonidamine analogs
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
HUP0301179A2 (hu) Módosított VIII-as faktor
NO20055741D0 (no) Nye kjemiske forbindelser
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
TW200628168A (en) Use of organic compounds
MXPA05011830A (es) Peptidos para uso en el tratamiento de la obesidad.
ATE518531T1 (de) Alpha-humulene zur verwendung bei der prophylaxe oder behandlung der entzündlichen schmerzen und des ödems
BR0313522A (pt) Uso de oligonucleotìdeos anti-sentido para inibir a expressão de akt-1
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
TR200200278T2 (tr) Kalsilitik bileşimler
DE602004022921D1 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
CA104143S (en) Brush

Legal Events

Date Code Title Description
8364 No opposition during term of opposition